SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Approval for Wipes System from VAH in Germany

6 Jun 2011 07:00

RNS Number : 8688H
Tristel PLC
06 June 2011
 



 

 

Tristel plc

("Tristel" or "the Company")

AIM: TSTL

 

Approval for Wipes System from VAH in Germany

 

Tristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that it has received confirmation from the German Association for Applied Hygiene (Verbund fur Angewandte Hygiene or VAH), that its Wipes System has been included on the VAH list of approved disinfectants.

Tristel's patented Wipes System is widely used worldwide for the decontamination of the small and delicate medical instruments used in hospital departments such as ear, nose and throat (ENT), cardiology and ultrasound. The Wipes System was recently recognised by the ENT Societies in the United Kingdom and Italy as a preferred disinfection technique, and has also recently been approved by Australia's Therapeutic Goods Association.

Inclusion in the VAH list will enable Tristel to sell its Wipes System to public hospitals in Germany. Hitherto, the Wipes System has only been available to private hospitals and clinics. In the 8 month period that Tristel's German branch has been fully operational, the Wipes System has been adopted by 73 users in Germany. The VAH certification significantly expands the Wipes System's sales potential in Europe's largest hospital market. Germany has 2,100 hospitals and there are approximately 4,000 ENT consultants practising in the country. This compares to approximately 600 public and private hospitals combined in the United Kingdom where the Wipes System is used in over 70% of ENT clinics. Wipes System sales in the United Kingdom in the financial year ended 30 June 2010 were £1,449,000.

Paul Swinney, Chief Executive of Tristel, said: "The Wipes System is a unique product that is widely patented. With its inclusion in Germany's VAH list we have made another great stride in establishing the Wipes System as the gold standard for the types of medical instrument used in specialist hospital departments such as ENT and cardiology. Such specialist departments can be found in almost all hospitals worldwide, and are the areas specifically targeted as part of Tristel's international expansion plan."

 

 

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

finnCap

Geoff Nash / Charlotte Stranner (Corporate Finance)

Simon Starr (broking)

Tel: 020 7600 1658

Walbrook PR

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07866 384 707

paul.cornelius@walbrookir.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
REABUGDLSXGBGBX
Date   Source Headline
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights
15th May 20257:00 amRNSCFO succession planning
12th May 20257:00 amRNSFDA clearance for Tristel OPH
10th Apr 20257:00 amRNSAdditional info. submitted to FDA for Tristel OPH
9th Apr 20257:00 amRNSPublication of Poster by Mayo Clinic & US update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.